Introduction and Moderation:
Gaetano Guglielmi, ICPerMed Secretariat, Italian Ministry of Health, Italy
NAGEN 1000: An example of a Project for Regional Implementation of Personalised Genomic Medicine in Healthcare
Angel Alonso, Navarrabiomed, Spain
Proposal of Reccomendations for a National Strategy on personalized Medicine Report
Consuelo Martin de Dios, Fundación Instituto Roche, Spain
In vivo evidence for ribavirin-induced mutagenesis of the hepatitis E virus genome
Daniel Todt, Ruhr-University Bochum, Germany
ICPerMed Member, Italian Ministry of Health, Italy
Gaetano Guglielmi MD PhD, is the Head of the Office of Health Research, DG for Research and Innovation in Healthcare. Since 2009 he is national representative in several international and European research programs such as ERA-NET NEURON, JPco-fuND, EuroNanoMed, E-Rare, ERA PerMed, EraCoSymed, JPIAMR, ERA-CVD, Infect-ERA and JPI MYBL, AAL and deputy coordinator in TRANSCAN and TRANSCAN-2. Guglielmi is responsible for the verification of research activities IRCCS and related management of funds.
After his medical degree, Angel Alonso was trained as a clinical geneticist and researcher in human genetics, serving in several senior clinical positions and research group leaderships for the last 20 years in Spain and the UK. Alonso paid a special attention to cancer genetics which became the greatest part of his scientific interest for a good number of years. In 2016, after holding a position at North East & North Cumbria NHS Genomic Medicine Centre, he started planning the design of the NAGEN 1000 project. Since then, Alonso felt strongly committed to the implementation of genomic medicine for the development of personalised medicine in public health services, and he has been very actively involved in numerous development strategic actions, being advisor of the Spanish Senate Commission for Genomic and Personalised Medicine and Secretary of Personalised Medicine Commission of the Spanish Society of Human Genetics AEGH.
Fundación Instituto Roche, Spain
Bachelor of Science specializing in Fundamental Biology by the Complutense University of Madrid (Spain). She has taken Doctorate courses in Genetic Engineering, Metabolism and Biotoxicology.
She has also completed postgraduate studies in Marketing, Financial Foundations for Management and Lobby and Public Affairs among others.
With more than 30 years of experience in the Pharmaceutical Industry in several laboratories where she has held different positions in different Departments: Medical, Marketing and Patient Access. At present, since February 2016 she is Managing Director of Roche Institute Foundation (Foundation that Roche Farma has set up in 2004 in Spain).
Ruhr-University Bochum, Germany
Daniel Todt is a bioinformatician in virology research at the Ruhr University in Bochum, Department of Molecular and Medical Virology. After his studies in bioinformatics and biomedicine, he did his PhD in 2017 at Twincore – Institute for Experimental and Clinical Infection Research in Hannover. His special concern lays in the emergence of drug resistance mutations in the genomes of RNA viruses, particularly hepatitis virus. The rapid translation of findings into clinical applications in personalised infection medicine is of particular interest to him.
On 20/21 November 2018, the DLR Project Management Agency took part in the ICPerMed Conference 2018 'Personalised Medicine in Action' as one of the organisers. In its function as editor of the website of the 'ICPerMed International Consortium', the DLR Project Management Agency agreed to upload the presentations held during this event to this website thus making them available for download in pdf format subject to the express consent of the speakers concerned. DLR, as the uploading entity, has not monitored the contents of these presentations in any way. In case of incorrect contents, copyright infringements or other violations of the law, please contact the ICPerMed Secretariat (e-mail: ICPerMed@dlr.de). Any offending material will be removed immediately.